Eli Lilly stated LY-CoV555 was “well tolerated” without the observation of any drug-related serious events. And that adverse events were similar to placebo. However, the exact incidence of milder drug reactions which could affect patient acceptance were not given.
Most hospitals have implemented stringent visitor restrictions that don’t allow anyone to visit, even during end of life. While an understandable public health and infection prevention measure, it has generated some concern.
Patients afflicted with COVID-19 have an increased susceptibility to antibiotic resistant infections both from prolonged hospitalizations and the use of immunocompromising agents such as dexamethasone.